论文部分内容阅读
表线性膀胱癌的特点是多灶性和高复发性。1961年Meenema等用膀胱腔内灌注噻替哌治疗复发性表线膀胱癌。但是噻替哌分子量小,易被尿路上皮吸收,造成骨髓抑制和膀胱刺激症状,同时不完全反应率达60％。 1967年日本Shida等首先用丝裂霉素C治疗表浅性膀胱癌,取得满意疗效。1976年Soloway等用鼠模型研究腔内化疗药物对移行细胞癌的作用,发现丝裂霉素C的完全反应率为45％,部分反应率为33％。另外,噻替哌治疗失败者中75％仍对丝裂霉素反应(完全或部分)。丝裂霉素C是一种烷化剂,静脉注射可致严重
Linear bladder cancer is characterized by multifocal and high recurrence. In 1961, Meenema et al used intravesical instillation of thiabendazole in the treatment of recurrent bladder cancer. However, thiotepa molecular weight is small, easily absorbed by the urinary tract epithelium, resulting in bone marrow suppression and irritation to the bladder, while incomplete response rate of 60%. 1967 Japan Shida other first with mitomycin C treatment of superficial bladder cancer, and achieved satisfactory results. In 1976, Soloway et al. Used mouse models to study the effect of intracavitary chemotherapeutic drugs on transitional cell carcinoma. The complete response rate of mitomycin C was 45% and the partial response rate was 33%. In addition, 75% of patients who failed treatment with thiotepa still reacted (completely or partially) to mitomycin. Mitomycin C is an alkylating agent and can be very toxic by intravenous injection